This document provides a summary of McKesson Corporation's presentation at the 2002 Raymond James Conference. It discusses McKesson's strong financial performance over the past years, with revenue growth of 15% in the most recent quarter and EPS growth of 31%. The presentation reviews each of McKesson's business units - Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions - and their strategies, market positions, and financial results. McKesson's goals are continued margin expansion and leadership across its business segments to deliver sustained financial performance and value for customers and shareholders.
This document summarizes McKesson Corporation's presentation at the 2002 Credit Suisse First Boston Healthcare Conference. McKesson reported strong Q2 FY03 results with 15% revenue growth and 31% EPS growth. Pharmaceutical Solutions saw 27% operating profit growth driven by generics. Information Solutions saw 79% operating profit growth and expanding margins. Medical-Surgical Solutions saw a 92% decline but efforts were underway to turn it around. McKesson outlined opportunities across its business units to drive continued growth and margin expansion through leadership in pharmaceutical distribution and clinical healthcare IT.
This document summarizes McKesson Corporation's presentation at the 2002 Merrill Lynch Healthcare Services Conference. McKesson is the largest healthcare services company, with $46 billion in revenues. It has seen seven consecutive quarters of earnings per share growth above 30% across its pharmaceutical, medical-surgical, and information solutions business units. McKesson aims to continue delivering industry-leading solutions and margin expansion across its business units to create value for customers and shareholders.
This document summarizes John Hammergren's presentation at the 2003 JP Morgan Healthcare Conference. The presentation highlights McKesson's business units and growth opportunities. McKesson has seen positive momentum in Pharmaceutical Solutions and Information Solutions through revenue growth and margin expansion. Medical-Surgical Solutions is undergoing a turnaround. McKesson is well-positioned for continued growth and margin expansion driven by favorable market factors such as an aging population and focus on higher quality and lower costs in healthcare.
2003 Merrill Lynch Global Healthcare Conferencefinance2
This document summarizes John Hammergren's presentation on February 5, 2003 at the 2003 Merrill Lynch Global Healthcare Conference. The presentation discusses McKesson Corporation's market overview and strategy, business unit performance, focus on innovation, and key highlights. McKesson is the largest healthcare services company in North America, with $46 billion in annual revenues across pharmaceutical, medical-surgical, and information solutions. The presentation notes McKesson's continued revenue growth and margin expansion across business units, driven by favorable market factors of an aging population demanding higher quality care.
Lehman Brothers 2003 Global Heathcare Conferencefinance2
This document provides an overview of John Hammergren's presentation at the 2003 Lehman Brothers Global Healthcare Conference. Some key points:
1) McKesson is the largest healthcare services company in North America with three segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions.
2) Pharmaceutical Solutions is experiencing revenue growth and expanding operating margins. Information Solutions is also growing revenues and expanding margins. Medical-Surgical Solutions is undergoing a turnaround.
3) McKesson aims to create long-term customer relationships through innovative solutions that improve quality and reduce costs across the healthcare system.
This document summarizes John Hammergren's presentation at the 2002 Bear Stearns Healthcare Conference. The presentation discusses McKesson's strategies and financial performance. It highlights that McKesson provides pharmaceutical and medical supplies distribution, clinical software, and other healthcare IT solutions. It also notes McKesson's focus on driving automation, generics sales, and clinical leadership to improve margins and execution. Finally, it summarizes McKesson's strong financial performance over the previous quarters with continued revenue and earnings growth.
McKesson Investor/Analyst Day (Part II: Pharmaceutical and Medical-Surgical...finance2
The document provides an overview and agenda for a McKesson Supply Solutions business meeting. It summarizes the company's financial performance, growth strategies across different business units including pharmaceuticals, automation, health solutions, and medical-surgical solutions. It highlights momentum in revenue growth, operating margin expansion, and market leadership across North America. The agenda outlines plans to continue this momentum through business unit execution, specialty pharmaceutical services, and driving further operating margin improvements.
cardinal health UBS Global Healthcare Services Conference 2009finance2
George Barrett, Vice Chairman and CEO of Cardinal Health, presented on the company post-spin. The new Cardinal Health will be a leading provider of products and services across the healthcare supply chain, serving over 50,000 customers with $90 billion in annual revenue. It will focus on the pharmaceutical and medical products segments to provide solutions that improve customer efficiency and quality. Cardinal Health is well-positioned to address evolving industry needs such as cost containment and care coordination due to its broad footprint and capabilities.
This document summarizes McKesson Corporation's presentation at the 2002 Credit Suisse First Boston Healthcare Conference. McKesson reported strong Q2 FY03 results with 15% revenue growth and 31% EPS growth. Pharmaceutical Solutions saw 27% operating profit growth driven by generics. Information Solutions saw 79% operating profit growth and expanding margins. Medical-Surgical Solutions saw a 92% decline but efforts were underway to turn it around. McKesson outlined opportunities across its business units to drive continued growth and margin expansion through leadership in pharmaceutical distribution and clinical healthcare IT.
This document summarizes McKesson Corporation's presentation at the 2002 Merrill Lynch Healthcare Services Conference. McKesson is the largest healthcare services company, with $46 billion in revenues. It has seen seven consecutive quarters of earnings per share growth above 30% across its pharmaceutical, medical-surgical, and information solutions business units. McKesson aims to continue delivering industry-leading solutions and margin expansion across its business units to create value for customers and shareholders.
This document summarizes John Hammergren's presentation at the 2003 JP Morgan Healthcare Conference. The presentation highlights McKesson's business units and growth opportunities. McKesson has seen positive momentum in Pharmaceutical Solutions and Information Solutions through revenue growth and margin expansion. Medical-Surgical Solutions is undergoing a turnaround. McKesson is well-positioned for continued growth and margin expansion driven by favorable market factors such as an aging population and focus on higher quality and lower costs in healthcare.
2003 Merrill Lynch Global Healthcare Conferencefinance2
This document summarizes John Hammergren's presentation on February 5, 2003 at the 2003 Merrill Lynch Global Healthcare Conference. The presentation discusses McKesson Corporation's market overview and strategy, business unit performance, focus on innovation, and key highlights. McKesson is the largest healthcare services company in North America, with $46 billion in annual revenues across pharmaceutical, medical-surgical, and information solutions. The presentation notes McKesson's continued revenue growth and margin expansion across business units, driven by favorable market factors of an aging population demanding higher quality care.
Lehman Brothers 2003 Global Heathcare Conferencefinance2
This document provides an overview of John Hammergren's presentation at the 2003 Lehman Brothers Global Healthcare Conference. Some key points:
1) McKesson is the largest healthcare services company in North America with three segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions.
2) Pharmaceutical Solutions is experiencing revenue growth and expanding operating margins. Information Solutions is also growing revenues and expanding margins. Medical-Surgical Solutions is undergoing a turnaround.
3) McKesson aims to create long-term customer relationships through innovative solutions that improve quality and reduce costs across the healthcare system.
This document summarizes John Hammergren's presentation at the 2002 Bear Stearns Healthcare Conference. The presentation discusses McKesson's strategies and financial performance. It highlights that McKesson provides pharmaceutical and medical supplies distribution, clinical software, and other healthcare IT solutions. It also notes McKesson's focus on driving automation, generics sales, and clinical leadership to improve margins and execution. Finally, it summarizes McKesson's strong financial performance over the previous quarters with continued revenue and earnings growth.
McKesson Investor/Analyst Day (Part II: Pharmaceutical and Medical-Surgical...finance2
The document provides an overview and agenda for a McKesson Supply Solutions business meeting. It summarizes the company's financial performance, growth strategies across different business units including pharmaceuticals, automation, health solutions, and medical-surgical solutions. It highlights momentum in revenue growth, operating margin expansion, and market leadership across North America. The agenda outlines plans to continue this momentum through business unit execution, specialty pharmaceutical services, and driving further operating margin improvements.
cardinal health UBS Global Healthcare Services Conference 2009finance2
George Barrett, Vice Chairman and CEO of Cardinal Health, presented on the company post-spin. The new Cardinal Health will be a leading provider of products and services across the healthcare supply chain, serving over 50,000 customers with $90 billion in annual revenue. It will focus on the pharmaceutical and medical products segments to provide solutions that improve customer efficiency and quality. Cardinal Health is well-positioned to address evolving industry needs such as cost containment and care coordination due to its broad footprint and capabilities.
The document summarizes McKesson Corporation's investor/analyst day presentation from June 7, 2002. It discusses the company's strategy, financial performance, goals for its supply management, information solutions, and other business segments. Key points include revenue and earnings growth in recent years, goals to increase market share and margins across various segments, and continued investment in new products and services. Financial metrics like EBIT, EPS, cash flow, and return on capital are presented for 2000-2002 with most showing strong growth.
Banc of America Securities 2006 Health Care Conference Presentationfinance2
Jeff Campbell, Executive Vice President and CFO of McKesson Corporation, presented at the Bank of America Healthcare Conference on May 17, 2006. McKesson is a healthcare services and information technology company founded in 1833 with over $88 billion in revenues in FY2006. Campbell discussed McKesson's market leading positions in pharmaceutical distribution and medical-surgical supplies, as well as its growth strategy of creating long-term customer relationships through customized solutions. He also reviewed McKesson's financial performance over the past six years, which has included strong revenue growth and increasing diluted earnings per share, excluding one-time litigation charges.
Robert Baird Growth Stock Conference Presentationsfinance2
Jeff Campbell, Executive Vice President and CFO of McKesson Corporation, presented at the Robert W. Baird Conference on May 10, 2006. The presentation provided an overview of McKesson, including its financial performance over the past six years, market positioning, and growth opportunities. McKesson's revenues have grown from $36.7 billion in FY00 to $88.1 billion in FY06, and diluted EPS has increased from $0.65 to $2.44 over the same period. The presentation also reviewed McKesson's segments and their financial results, guidance for FY07 EPS, and positioning in key healthcare areas.
Walgreen Co. First Quarter 2009 Earnings Conference finance4
The document summarizes Walgreen's first quarter 2009 conference call. It discusses key highlights such as sales being up 6.6% but earnings down 10.4%. It also outlines strategic initiatives like slowing new store openings, enhancing the customer experience, and targeting $1 billion in annual cost reductions. The presentation provides an overview of the company's financial performance and position for future growth.
The document provides an overview of Wolters Kluwer's half-year 2011 results. It highlights 3% revenue growth and 1% organic growth. It also notes the planned divestment of the pharma business to focus on leading positions in professional information and clinical decision support solutions. Divisional performances are summarized, including strong growth in Legal, Health, and Financial & Compliance Services. Clinical Solutions and Medical Research are emphasized as key growth drivers.
This document outlines a business plan for producing therapeutic proteins like vaccines and alpha-1 antitrypsin using tobacco plants. It discusses using tobacco's manufacturing capabilities to rapidly and cost-effectively produce proteins. Target markets include seasonal flu vaccines, pandemic flu vaccines, and alpha-1 antitrypsin for treating deficiencies. The plan involves outsourcing manufacturing activities and establishing partnerships with larger biotech companies and government organizations. Financial metrics like costs, pricing, and capital requirements are considered to evaluate feasibility and profitability.
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011Nathan White, CPC
This document summarizes a presentation on creating an optimal commercial reimbursement landscape for pharmaceutical products. The presentation discusses the complexities of proving value to payers in light of healthcare reform uncertainties and a changing regulatory environment. It provides two case studies on companies that failed to consider reimbursement challenges and offers lessons on strategic planning to meet regulatory and reimbursement needs. The goal is developing a clinical and regulatory strategy that ensures reimbursement resonance with payers and reduces patient access barriers.
cardinal health Conference Call Presentationfinance2
Cardinal Health presented information on its planned spin-off of its clinical and medical products businesses into a separate company. It discussed the rationale for the separation, including allowing each business to focus on its strategic goals and access capital. It outlined key steps and milestones to completing the spin-off. Cardinal Health also presented overviews of the businesses that would comprise each company after the separation and their leadership teams, capital structures, and growth opportunities.
Drug delivery technology is a growing $50 billion market that is expected to see increased mergers and acquisitions activity. Drug delivery technologies help pharmaceutical companies respond to expiring patents and enable new drug formulations. Recent deals in the drug delivery sector include Philips acquiring Respironics and SpineOvation acquiring Discogen. We expect to see continued consolidation in the drug delivery field as companies combine technologies and services to achieve profitability and access new markets.
This 2009 annual report summarizes Medco Health Solutions' financial and operational performance for the year. Key highlights include record revenues of $59.8 billion, net income of $1.28 billion, and adjusted prescription volume of 898.8 million. The company saw growth in specialty pharmacy revenues and generic dispensing rates. Medco also advanced initiatives in areas like pharmacogenomics, international expansion, and a new online health store. The report discusses Medco's focus on making medicine smarter through clinical leadership and innovation.
The document discusses scaling medicine through design and accelerating data to improve quality and lower costs. It suggests that engineers and designers are essential to hack business models and define experiments to test assumptions. Some areas proposed to focus on include incentives, health reform, and the intersection of high tech and med tech. The document outlines several tools that can be used to map and hack healthcare business models, including a business model canvas, care delivery value chain, and health model canvas. It provides the MIT example of Ginger.io and encourages attendees to "please hack healthcare."
Staying Relevant in a High Volume, Commoditized, Medical Device Product Line ...marcus evans Network
Beth Krenzer, Cardinal Health - Speaker at the marcus evans Medical Device Manufacturing Summit Spring 2012, held in Las Vegas, NV, delivered his presentation entitled Staying Relevant in a High Volume, Commoditized, Medical Device Product Line in Manufacturing (Insourced and Outsourced)
The document is a business intelligence portfolio for Chris Bull containing examples of his skills and experience in areas such as data modeling, SQL programming, SQL Server Integration Services, SQL Server Analysis Services, MDX programming, SQL Server Reporting Services, PerformancePoint Server, and SharePoint Server. It includes samples of his work developing ETL processes, cubes, reports, and other BI solutions. It also provides a summary of his 14 years of IT experience and 2 recommendations from academic references.
Manufacturer of Commercial Chairs, Meeting Room Chairs & Executive Series Chairs offered by Divine Chairs Pvt. Ltd. from Navi Mumbai, Maharashtra, India.
Graduate School pays off for University- bussiness story ready to editFalicya Crace
Coastal Carolina University offers graduate programs in four schools that are profitable investments for the university. With over 600 graduate students enrolled in 2014, Coastal brought in nearly $2 million in tuition that year. While revenue is important, graduate programs also enhance the academic community through increased intellectual discourse. Certain science programs may have higher costs but are offset by additional grants and contracts attracted by faculty research. Coastal aims to expand its graduate offerings and expects to generate millions more in tuition over the next four years.
Design: From Engineer to Designer PerspectiveAlan Ho
The document discusses design from the perspectives of engineers and interaction designers. For engineers, the design process considers F3 - form, fit, and function. However, designers sometimes overly focus on F3 and lose sight of other essentials like finish and meaning that mainly concern users. The most important element for interaction design is meaning, as designers are creating for humans, not machines, and users make sense of designs based on meaning. Designers are reminded to always include finish and meaning alongside F3 in their designs.
Online Customer Order Booking Portal (eCommerce Solution)Mayank Chanlawala
Application suggest vendor product like if we consider Tata steel then this portal will display all the product and it’s descriptions. Once the user select product and it’s his requirement then system will start searching available inventory from all service center , vendor , all plants. If system finds required material it will suggest the free material and for remaining material suggest lead time(delivery time).
The document summarizes McKesson Corporation's investor/analyst day presentation from June 7, 2002. It discusses the company's strategy, financial performance, goals for its supply management, information solutions, and other business segments. Key points include revenue and earnings growth in recent years, goals to increase market share and margins across various segments, and continued investment in new products and services. Financial metrics like EBIT, EPS, cash flow, and return on capital are presented for 2000-2002 with most showing strong growth.
Banc of America Securities 2006 Health Care Conference Presentationfinance2
Jeff Campbell, Executive Vice President and CFO of McKesson Corporation, presented at the Bank of America Healthcare Conference on May 17, 2006. McKesson is a healthcare services and information technology company founded in 1833 with over $88 billion in revenues in FY2006. Campbell discussed McKesson's market leading positions in pharmaceutical distribution and medical-surgical supplies, as well as its growth strategy of creating long-term customer relationships through customized solutions. He also reviewed McKesson's financial performance over the past six years, which has included strong revenue growth and increasing diluted earnings per share, excluding one-time litigation charges.
Robert Baird Growth Stock Conference Presentationsfinance2
Jeff Campbell, Executive Vice President and CFO of McKesson Corporation, presented at the Robert W. Baird Conference on May 10, 2006. The presentation provided an overview of McKesson, including its financial performance over the past six years, market positioning, and growth opportunities. McKesson's revenues have grown from $36.7 billion in FY00 to $88.1 billion in FY06, and diluted EPS has increased from $0.65 to $2.44 over the same period. The presentation also reviewed McKesson's segments and their financial results, guidance for FY07 EPS, and positioning in key healthcare areas.
Walgreen Co. First Quarter 2009 Earnings Conference finance4
The document summarizes Walgreen's first quarter 2009 conference call. It discusses key highlights such as sales being up 6.6% but earnings down 10.4%. It also outlines strategic initiatives like slowing new store openings, enhancing the customer experience, and targeting $1 billion in annual cost reductions. The presentation provides an overview of the company's financial performance and position for future growth.
The document provides an overview of Wolters Kluwer's half-year 2011 results. It highlights 3% revenue growth and 1% organic growth. It also notes the planned divestment of the pharma business to focus on leading positions in professional information and clinical decision support solutions. Divisional performances are summarized, including strong growth in Legal, Health, and Financial & Compliance Services. Clinical Solutions and Medical Research are emphasized as key growth drivers.
This document outlines a business plan for producing therapeutic proteins like vaccines and alpha-1 antitrypsin using tobacco plants. It discusses using tobacco's manufacturing capabilities to rapidly and cost-effectively produce proteins. Target markets include seasonal flu vaccines, pandemic flu vaccines, and alpha-1 antitrypsin for treating deficiencies. The plan involves outsourcing manufacturing activities and establishing partnerships with larger biotech companies and government organizations. Financial metrics like costs, pricing, and capital requirements are considered to evaluate feasibility and profitability.
BIO Windhover Pharmaceutical Strategic Alliances Conference April 2011Nathan White, CPC
This document summarizes a presentation on creating an optimal commercial reimbursement landscape for pharmaceutical products. The presentation discusses the complexities of proving value to payers in light of healthcare reform uncertainties and a changing regulatory environment. It provides two case studies on companies that failed to consider reimbursement challenges and offers lessons on strategic planning to meet regulatory and reimbursement needs. The goal is developing a clinical and regulatory strategy that ensures reimbursement resonance with payers and reduces patient access barriers.
cardinal health Conference Call Presentationfinance2
Cardinal Health presented information on its planned spin-off of its clinical and medical products businesses into a separate company. It discussed the rationale for the separation, including allowing each business to focus on its strategic goals and access capital. It outlined key steps and milestones to completing the spin-off. Cardinal Health also presented overviews of the businesses that would comprise each company after the separation and their leadership teams, capital structures, and growth opportunities.
Drug delivery technology is a growing $50 billion market that is expected to see increased mergers and acquisitions activity. Drug delivery technologies help pharmaceutical companies respond to expiring patents and enable new drug formulations. Recent deals in the drug delivery sector include Philips acquiring Respironics and SpineOvation acquiring Discogen. We expect to see continued consolidation in the drug delivery field as companies combine technologies and services to achieve profitability and access new markets.
This 2009 annual report summarizes Medco Health Solutions' financial and operational performance for the year. Key highlights include record revenues of $59.8 billion, net income of $1.28 billion, and adjusted prescription volume of 898.8 million. The company saw growth in specialty pharmacy revenues and generic dispensing rates. Medco also advanced initiatives in areas like pharmacogenomics, international expansion, and a new online health store. The report discusses Medco's focus on making medicine smarter through clinical leadership and innovation.
The document discusses scaling medicine through design and accelerating data to improve quality and lower costs. It suggests that engineers and designers are essential to hack business models and define experiments to test assumptions. Some areas proposed to focus on include incentives, health reform, and the intersection of high tech and med tech. The document outlines several tools that can be used to map and hack healthcare business models, including a business model canvas, care delivery value chain, and health model canvas. It provides the MIT example of Ginger.io and encourages attendees to "please hack healthcare."
Staying Relevant in a High Volume, Commoditized, Medical Device Product Line ...marcus evans Network
Beth Krenzer, Cardinal Health - Speaker at the marcus evans Medical Device Manufacturing Summit Spring 2012, held in Las Vegas, NV, delivered his presentation entitled Staying Relevant in a High Volume, Commoditized, Medical Device Product Line in Manufacturing (Insourced and Outsourced)
The document is a business intelligence portfolio for Chris Bull containing examples of his skills and experience in areas such as data modeling, SQL programming, SQL Server Integration Services, SQL Server Analysis Services, MDX programming, SQL Server Reporting Services, PerformancePoint Server, and SharePoint Server. It includes samples of his work developing ETL processes, cubes, reports, and other BI solutions. It also provides a summary of his 14 years of IT experience and 2 recommendations from academic references.
Manufacturer of Commercial Chairs, Meeting Room Chairs & Executive Series Chairs offered by Divine Chairs Pvt. Ltd. from Navi Mumbai, Maharashtra, India.
Graduate School pays off for University- bussiness story ready to editFalicya Crace
Coastal Carolina University offers graduate programs in four schools that are profitable investments for the university. With over 600 graduate students enrolled in 2014, Coastal brought in nearly $2 million in tuition that year. While revenue is important, graduate programs also enhance the academic community through increased intellectual discourse. Certain science programs may have higher costs but are offset by additional grants and contracts attracted by faculty research. Coastal aims to expand its graduate offerings and expects to generate millions more in tuition over the next four years.
Design: From Engineer to Designer PerspectiveAlan Ho
The document discusses design from the perspectives of engineers and interaction designers. For engineers, the design process considers F3 - form, fit, and function. However, designers sometimes overly focus on F3 and lose sight of other essentials like finish and meaning that mainly concern users. The most important element for interaction design is meaning, as designers are creating for humans, not machines, and users make sense of designs based on meaning. Designers are reminded to always include finish and meaning alongside F3 in their designs.
Online Customer Order Booking Portal (eCommerce Solution)Mayank Chanlawala
Application suggest vendor product like if we consider Tata steel then this portal will display all the product and it’s descriptions. Once the user select product and it’s his requirement then system will start searching available inventory from all service center , vendor , all plants. If system finds required material it will suggest the free material and for remaining material suggest lead time(delivery time).
valero energy Quarterly and Other SEC Reports 2004 3rd finance2
This document summarizes the key terms of a Restricted Unit Agreement between Valero Energy Corporation and William E. Greehey, Valero's Chief Executive Officer. Under the agreement, Greehey is granted 138,350 restricted units representing the right to receive cash payments from Valero on specified vesting dates. The cash payments will equal the number of units vesting multiplied by the fair market value of Valero stock on the vesting date. Greehey will also receive periodic cash payments equal to declared dividends on Valero stock multiplied by the number of unvested units held. The restricted units will vest in increments over time, with 46,117 units vesting on October 21, 2005.
Morgan Stanley Dean Witter reported record quarterly operating results for Q2 1999, with net income up 35% to $1.15 billion and diluted EPS up 42% to $1.95 per share. Net revenues increased 23% to $5.7 billion, driven by strong performances across institutional securities, investment banking, and private client businesses. The company also saw improved credit quality and higher transaction volume in its credit services segment. Overall, Morgan Stanley Dean Witter had another very successful quarter with significant revenue and earnings growth across all business lines.
McKesson reported substantial progress in the past fiscal year by meeting key goals across its operations. In its supply management business, revenues grew 13% while operating margin improved 14 basis points. The information technology segment stabilized its customer and employee bases and saw its first year-over-year revenue gain in seven quarters. Looking ahead, McKesson is well positioned for continued growth due to positive industry fundamentals and its integrated solutions approach.
JPMorgan Chase Leadership team and our businessesfinance2
JPMorgan Chase's leadership team operates through multiple divisions to provide financial services globally. In 2007, most divisions achieved record results, including Commercial Banking which increased net income 12% and net revenue 8% to record levels. Looking ahead, leaders intend to capitalize on opportunities outside the U.S., enhance products and services, and continue building on momentum despite economic uncertainty.
AIG Conference Call Credit Presentation - August 7, 2008finance2
This document provides a summary of AIG Financial Products' (AIGFP) super senior credit derivative portfolio as of June 30, 2008. Some key points:
- AIGFP's net notional exposure was $441 billion, down from $469.5 billion last quarter. The portfolio included corporate, residential mortgage, and multi-sector CDO exposures.
- Losses on the underlying collateral remained low, ranging from 0.01-1.06% depending on the sector, well below the weighted average attachment points.
- However, rating agencies downgraded approximately $36.4 billion (63%) of the multi-sector CDO portfolio with subprime exposure, reflecting deterioration in those markets.
This document is a share exchange agreement between The Bear Stearns Companies Inc. and JPMorgan Chase & Co. dated March 24, 2008. Key points:
- Bear Stearns agrees to issue 95 million shares to JPMorgan in exchange for 20,665,350 JPMorgan shares and JPMorgan's entry into related agreements.
- The audit committee of Bear Stearns' board unanimously approved relying on a NYSE rule exception to issue the shares without stockholder approval.
- The agreement includes representations from both companies regarding authorization, valid issuance of shares, and compliance with laws.
- Closing is conditioned on there being no legal prohibitions on the transaction and
Morgan Stanley reported net income of $735 million for Q3 2001, down 41% from $1.246 billion in Q3 2000. Net revenues were $5.3 billion, down 16% year-over-year. The annualized return on equity was 15% for the quarter. While global economic concerns increased, Morgan Stanley believes in long-term growth opportunities and will increase share repurchases. Securities net income was $414 million, down 50% from last year's strong third quarter due to lower market activity. Credit services net income was $196 million, down 14%, with higher net charge-offs offsetting increases in interest income and fees.
Morgan Stanley Dean Witter announced record full-year and fourth quarter results. For the full year, net income was $5.5 billion, up 14% from the prior year. Fourth quarter net income was $1.2 billion, down 26% from the previous year's fourth quarter. The company's securities, asset management, and credit services businesses all achieved record annual net income. The board also declared a 15% increase in the quarterly dividend to $0.23 per share.
cardinal health Q1 2007 Earnings Presentationfinance2
This document summarizes Cardinal Health's first quarter earnings for fiscal year 2007. It provides an overview of Cardinal Health's consolidated and segment financial results for the quarter, including revenue, operating earnings, earnings per share, and other key metrics. It notes growth over the prior year quarter for most measures. The document also outlines Cardinal Health's key value drivers and financial targets for fiscal year 2007, including targets for revenue growth, earnings per share, return on equity, and cash returned to shareholders.
Morgan Stanley Dean Witter reported strong second quarter 2000 results, with net income up 27% to $1.458 billion and earnings per share up 30% compared to the second quarter of 1999. All business segments performed well, with record results in securities and asset management. The company also announced an additional $1.5 billion stock repurchase authorization.
Bear Stearns 2003 Global Healthcare Conference Presentationfinance2
John Hammergren, CEO of McKesson Corporation, presented at the 2003 Bear Stearns Global Healthcare Conference. He outlined McKesson's mission to advance healthcare and success of its partners. McKesson offers comprehensive products and services across pharmaceutical distribution, medical supplies, automation technology, and clinical software. McKesson aims to leverage its size, customer base, and solutions to create value for customers and shareholders through improved quality, reduced costs, and sustained financial performance across its business segments.
John Hammergren, CEO of McKesson, presented an overview of the company's financial results and strategy at a Goldman Sachs healthcare conference. McKesson achieved 22% revenue growth and 20% earnings per share growth in fiscal year 2004. McKesson's strategy is to build strong customer relationships through comprehensive solutions, invest in innovative offerings, and create unique solutions to address emerging healthcare challenges. For fiscal year 2005, McKesson expects earnings per share between $2.20-$2.35, with revenues growing over 10% annually and mid-teens earnings growth once business changes are completed.
Credit Suisse First Boston Annual Health Care Conference Presentationfinance2
Paul Julian, president of McKesson Supply Solutions, presented at the CSFB 2003 Global Healthcare Conference. He discussed McKesson's mission to advance healthcare success through partnerships. McKesson offers comprehensive products, technology, and services across multiple divisions. Julian highlighted McKesson's strategy of leveraging its size, customer base, and solutions to improve quality and reduce costs. Financial results for the second quarter and first half of fiscal year 2004 showed revenue growth and increased profitability.
McKesson provides concise summaries of their business in 3 sentences:
McKesson is a leading healthcare services and information technology company with the #1 market share in pharmaceutical distribution, automation solutions, and medical-surgical supplies. They leverage their scale across business units like Pharmaceutical Solutions, Information Solutions, and Medical-Surgical Solutions to improve clinical outcomes and reduce costs for customers through their "One McKesson" strategy of comprehensive offerings and services. McKesson reported solid financial results for Q2 and the first half of FY04 with revenue growth of 14% and 27% EPS growth, driven by strong performance in Pharmaceutical Solutions.
Jeff Campbell, Executive Vice President and CFO of McKesson, presented at the Lehman Brothers Annual Healthcare Conference on March 31, 2005. The presentation provided an overview of McKesson, including that it is the largest pharmaceutical distributor in the US, Canada, and Mexico. It also discussed McKesson's strategy to bring together clinical knowledge, process expertise, technology, and resources to fundamentally change the cost and quality of healthcare. The presentation included financial highlights showing year-over-year revenue growth of 14% for Q3 and 16% for the first nine months, but also a $1.2 billion securities litigation settlement charge in Q3.
Credit Suisse First Boston Healthcare Conferencefinance2
John Hammergren, CEO of McKesson Corporation, presented an overview of the company and its business segments. McKesson is the largest pharmaceutical distributor in North America with additional businesses in medical supplies distribution and healthcare IT. In the first two quarters of fiscal year 2005, McKesson experienced revenue growth across all segments but declining operating margins in pharmaceutical distribution due to fewer than expected drug price increases. Hammergren outlined McKesson's strategy to transition pharmaceutical compensation models to be less dependent on price inflation and more focused on delivering value. For the full fiscal year, McKesson expects earnings per share to be between $2.00-$2.20.
Merrill Lynch Health Services Investor Conferencefinance2
John Hammergren, CEO of McKesson, presented an overview of the company and its healthcare businesses. McKesson's pharmaceutical distribution business saw 20% revenue growth in Q2 but declining margins due to fewer drug price increases. The medical-surgical and technology businesses grew revenues slightly with mixed profit results. For the fiscal year, McKesson expects EPS of $2.00-$2.20 assuming drug price increases within historical ranges.
The document provides an overview of McKesson Corporation's presentation to investors. It includes the following key points:
1) McKesson has a comprehensive offering of pharmaceutical, medical-surgical, and healthcare IT products and services. It is a leader in various healthcare sectors.
2) McKesson's vision is to build strong relationships and create solutions that address the major trends in healthcare including rising drug consumption, a focus on technology and patient safety, and controlling costs.
3) McKesson's FY04 financial results showed revenue growth of 22% and EPS growth of 16%. Goals for FY05 include continued revenue and profitability growth across business segments.
Jeff Campbell, Executive Vice President and CFO of McKesson, presented at the Goldman Sachs Healthcare Conference on June 14, 2006. McKesson generated $88 billion in revenues in fiscal year 2006, with strong growth over the past six years. McKesson has leadership positions across pharmaceutical distribution, medical supplies, and healthcare IT. The company is well positioned for ongoing growth through leadership in growing areas of healthcare and long-term customer relationships.
This document summarizes Jeff Campbell's presentation at the Baird 2005 Growth Stock Conference on May 11, 2005. Campbell discusses McKesson's business segments, including strong financial results and growth in pharmaceutical and medical-surgical solutions. Provider Technologies has experienced challenges but investments in innovation are paying off. For fiscal year 2006, McKesson expects revenue growth and operating cash flow over $1 billion, excluding the impact of settling a securities class action lawsuit.
This document summarizes John Hammergren's presentation at the Bear Stearns Global Healthcare Conference on September 14, 2004. The presentation provides an overview of McKesson Corporation, including who they are, their view of the healthcare industry, and how their businesses are responding to current challenges. Key highlights discussed include McKesson's strong financial performance, their strategy to fundamentally change healthcare costs and quality through technology and partnerships, and growth in their pharmaceutical distribution business.
George Barrett, Vice Chairman and Chief Executive Officer of Cardinal Health, presented on the company post-spin. Cardinal Health will focus on healthcare supply chain services and distribution, with over $90 billion in projected revenue. It will have two business segments - Pharmaceutical and Medical Products Distribution. Cardinal Health aims to strengthen customer focus, drive growth in generics, and leverage its scale and infrastructure to enable greater efficiency in the evolving healthcare system.
McKesson Corporation Investor and Analyst Day Presentationfinance2
This document summarizes the agenda and presentations for McKesson's 2006 Investor Day. The agenda included presentations from John Hammergren, Chairman and CEO, Jeff Campbell, EVP and CFO, Paul Julian, EVP, Group President, and Pam Pure, EVP, President of MPT, followed by a Q&A session. McKesson is well-positioned in growing healthcare services markets and has a track record of strong financial performance. It has leading market positions across its Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies segments. Healthcare spending and drug consumption are expected to continue rising driven by demographics, with an aging population requiring more medication.
McKesson HBOC is a global healthcare company providing pharmaceutical and medical supplies, information solutions, pharmacy automation, and sales and marketing services. It serves over 25,000 pharmacies, 5,000 hospitals, 35,000 physician practices, and other healthcare organizations. The company has experienced over 20% revenue growth annually from its supply chain management and information technology businesses. McKesson HBOC aims to continue growing these businesses and finding new ways to help customers reduce costs and improve patient care through organizational changes, new initiatives, and strategic partnerships.
McKesson Information Solutions HIMSS Briefingfinance2
McKesson Information Solutions is presenting on its business update and new product announcements. Customer satisfaction and employee satisfaction are improving based on survey results. Financial performance is strong with increased sales, income, and contracts. The Horizon software is ready for launch with momentum from existing customers. New products being announced at HIMSS include Pre-Service Manager, Horizon Care Access, and Horizon Business Folder to improve efficiency in resource management, revenue cycle, and medical imaging.
1) The document is a presentation by Cardinal Health about its Clinical & Medical Products division that is planned to be spun off as an independent company.
2) As a standalone company, it would have over $4 billion in annual revenue and focus solely on patient safety solutions.
3) It holds leading market positions in infusion, medication dispensing, infection prevention, and other areas, and aims to launch over 45 new products in the next 18 months.
HSIC is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. It has grown significantly since becoming a public company in 1995, with worldwide sales increasing from $616 million to $5.9 billion in 2007. HSIC services the dental, medical, and animal health markets through a broad product offering and value-added services. It has key strengths in sales and marketing expertise, centralized infrastructure, customer service, and practice management software. HSIC's strategies focus on expanding services to partner with customers and improve their efficiency, productivity, and profitability.
- Jeff Campbell, EVP and CFO of McKesson, presented at the UBS Healthcare Conference on February 8, 2012.
- McKesson is well-positioned for growth through leading market positions, a focus on higher margin businesses, and linking their distribution and technology segments.
- Their diversified portfolio across providers, payers, and connectivity provides a platform for steady long-term growth.
This document discusses considerations for launching a specialty product. It emphasizes the importance of demonstrating value through clinical and cost effectiveness data, ensuring patient access to therapy, and generating data to support value claims. It provides tips for defining goals, building an integrated team, and refining a launch strategy focused on these priorities. The strategy should consider innovative contracting, outcomes-based agreements, and communicating the right evidence to the right audiences. Overall, the document stresses that demonstrating value is critical for specialty product launches, especially with increased attention on healthcare costs.
The Home Depot Celebrates Hispanic Culture Through Color and Paint With Color...finance2
The Home Depot launched a new Hispanic-inspired paint color palette called Colores Origenes, featuring over 70 vibrant colors with Spanish names to reflect Latin American culture. Research showed painting is very popular among Hispanics, 59% of whom speak Spanish at home. The new paint line and increased Spanish signage and materials aim to better serve the growing Hispanic community. It was created with Behr Paint and will be sold exclusively at select Home Depot stores.
The Home Depot and AARP Launch Nationwide Workshopsfinance2
The Home Depot and AARP launched nationwide home improvement workshops customized for those aged 50 and over. The workshops will cover topics like home modifications for comfort and safety, saving money on energy bills, and basic maintenance. The workshops are part of an alliance between the two organizations to provide resources for aging homeowners as around 86 million Americans are currently over 50, comprising over 40% of the population.
Nearly Half of Americans Fail to Check Home Safety Devices at Daylight-Saving...finance2
A survey found that 47% of Americans did not check their home safety devices when changing their clocks for daylight saving time last year. Nearly three-quarters did not know when daylight saving time ends this year on October 30th. The Home Depot recommends using the end of daylight saving time as a reminder to check smoke detectors and carbon monoxide detectors by changing their batteries.
View Summary The Home Depot Celebrates the Olympic Spirit With Special Kids...finance2
The Home Depot announced a special Olympic-themed Kids Workshop to be held on November 5, 2005 at its stores nationwide. Children will build a wooden bobsled toy to celebrate the 2006 Winter Olympics. Selected stores will host Olympic athletes to help children and promote the Olympics. The Home Depot aims to teach kids DIY skills through these monthly workshops and has hosted over 13 million children since 1997.
The Home Depot Announces First Quarter Resultsfinance2
The Home Depot reported first quarter earnings of $356 million, down from $1 billion in the same period last year. This included a $543 million non-recurring charge for closing underperforming stores. Excluding this charge, earnings were $697 million. Sales decreased 3.4% to $17.9 billion due to a 6.5% drop in comparable store sales. The company's CEO acknowledged difficult market conditions and said the company would focus on investing in existing stores.
1) The document discusses Home Depot's merchandising strategy, which focuses on national brands, exclusive proprietary brands, and serving core customers through product knowledge transfer.
2) Home Depot aims to aggressively attack the market through its brand strategies, which leverage national brands, exclusive brands, and proprietary brands to differentiate, build preference, and offer selection.
3) Home Depot is transforming its merchandising approach through investments in talent, focused processes like seasonal planning and presentation, and new systems that provide merchants better data and tools.
home depot 2008 Annual Meeting of Stockholdersfinance2
This document summarizes The Home Depot's 2008 Annual Meeting of Shareholders. It provides an overview of the company's financial performance in 2007, including a 2% decrease in sales and an 11% decrease in net earnings per share. It also outlines the company's five priorities for 2007 which were investing in associate engagement, shopping environment, product availability, product excitement, and owning the professional customer. The outlook anticipates 2008 will be another difficult year with guidance for a 4-5% sales decrease and a 19-24% decrease in earnings per share. The company will continue investing in its key priorities and allocating capital efficiently.
The document is a transcript from The Home Depot's 2008 Investor Day conference. Frank Blake, the company's CEO, provides an overview of the company's strategic focus on improving the core retail business, exercising disciplined capital allocation, increasing returns on existing assets, and building sustained competitive advantages. He highlights progress made on priorities like associate engagement and product availability. While housing market conditions remain difficult, Blake emphasizes the company's long term strategy and goals, such as becoming a best in class merchandiser.
This document provides a financial overview and discussion of Home Depot's performance in Q1 2008 and outlook for 2008. Some key points:
- Q1 2008 sales were down 3.4% and operating income was down 56.5% due to housing market challenges.
- For 2008, Home Depot expects total sales to decline 4-5%, negative comps in the mid-to-high single digits, and operating margin decline of 170-210 basis points.
- Home Depot has a staggered debt maturity schedule with low refinancing risk and strong cash flow and liquidity.
- The company is focused on capital efficiency through store rationalization, supply chain improvements, and driving productivity across operations
Paul Raines discusses Home Depot's focus on store operations and customers. Key points include:
1) Home Depot has made multi-year investments to improve labor standards, launch an "Aprons on the Floor" program, and focus on foundational improvements like maintenance and store standards.
2) The company is focusing on two customer segments - professional contractors and multicultural customers - through programs like product knowledge certification for associates, understanding each group's purchasing patterns, and targeted marketing.
3) Initiatives like daytime freight, call center closures, and a new merchandising team have helped exceed Home Depot's $180 million goal in operating cost reductions to reinvest in labor.
home depot http://ir.homedepot.com/common/download/download.cfm?companyid=HD&...finance2
This document discusses Home Depot's supply chain transformation efforts from 2007 to 2008. It outlines goals of improving product availability, inventory management, and developing an optimal distribution network. Home Depot implemented regional distribution centers (RDCs) to better aggregate store orders, improve in-stock levels, and reduce supply chain costs. The RDCs were shown to simplify operations and had benefits including increased gross margins and improved inventory turns that could generate $1.5 billion in additional cash.
The document discusses a decline in private residential investment and subprime/Alt-A mortgages over the past few years which has negatively impacted the housing market. It then outlines Home Depot's strategic focus on increasing returns through disciplined capital allocation, investing in existing assets like employee training and supply chain improvements, and building sustained competitive advantages. Home Depot expects another difficult year in 2008 but believes these strategic initiatives position it for stronger future growth once market conditions normalize.
home depotForward Looking & Non-GAAP Disclosures finance2
The document discusses forward-looking statements made in today's presentations regarding the home improvement and housing markets, earnings guidance, and other factors affecting earnings and sales. It notes these statements are based on currently available information and expectations that could change. It also discusses non-GAAP financial measurements included in today's presentations, including total adjusted debt and earnings measures that exclude expected costs associated with store closures and pipeline changes. These supplemental measures are not a substitute for GAAP but provide useful information to investors.
home depot Bank of America 38th Annual Investment Conferencefinance2
Carol Tomé and Mark Holifield presented at the Bank of America 38th Annual Investment Conference. The presentation discussed (1) Home Depot's progress on five priorities including implementing store standards and supply chain improvements, (2) the evolution of Home Depot's capital efficiency strategy through investing in priorities and rationalizing non-core assets, and (3) expected benefits from supply chain improvements including gross margin expansion and $1.5 billion additional cash from reducing inventory turns.
- The Home Depot reported third quarter earnings for fiscal year 2008, with sales of $17.8 billion, down 6.2% from the previous year, and same-store sales down 8.3%. Earnings per share were $0.45.
- Challenging housing and home improvement markets continued to pressure results. Previously strong regions like the Northwest saw double-digit negative comps.
- While sales were weak across most departments, building materials had positive comps led by roofing and insulation. Initiatives to improve merchandising and focus on value are showing early signs of success through improved transactions, market share gains, and gross margin expansion despite volatile costs.
- Tightening credit availability also
- The Home Depot reported third quarter earnings for fiscal year 2008, with sales of $17.8 billion, down 6.2% from the previous year, and same-store sales down 8.3%. Earnings per share were $0.45.
- Challenging housing and home improvement markets continued to pressure results. Previously strong regions like the Northwest saw double-digit negative comps.
- While sales were weak across most departments, building materials had positive comps led by roofing and insulation. Initiatives to improve merchandising and focus on value are showing early signs of success through improved transactions, market share gains, and gross margin expansion despite volatile costs.
- Tightening credit availability also
Vicinity Jobs’ data includes more than three million 2023 OJPs and thousands of skills. Most skills appear in less than 0.02% of job postings, so most postings rely on a small subset of commonly used terms, like teamwork.
Laura Adkins-Hackett, Economist, LMIC, and Sukriti Trehan, Data Scientist, LMIC, presented their research exploring trends in the skills listed in OJPs to develop a deeper understanding of in-demand skills. This research project uses pointwise mutual information and other methods to extract more information about common skills from the relationships between skills, occupations and regions.
Fabular Frames and the Four Ratio ProblemMajid Iqbal
Digital, interactive art showing the struggle of a society in providing for its present population while also saving planetary resources for future generations. Spread across several frames, the art is actually the rendering of real and speculative data. The stereographic projections change shape in response to prompts and provocations. Visitors interact with the model through speculative statements about how to increase savings across communities, regions, ecosystems and environments. Their fabulations combined with random noise, i.e. factors beyond control, have a dramatic effect on the societal transition. Things get better. Things get worse. The aim is to give visitors a new grasp and feel of the ongoing struggles in democracies around the world.
Stunning art in the small multiples format brings out the spatiotemporal nature of societal transitions, against backdrop issues such as energy, housing, waste, farmland and forest. In each frame we see hopeful and frightful interplays between spending and saving. Problems emerge when one of the two parts of the existential anaglyph rapidly shrinks like Arctic ice, as factors cross thresholds. Ecological wealth and intergenerational equity areFour at stake. Not enough spending could mean economic stress, social unrest and political conflict. Not enough saving and there will be climate breakdown and ‘bankruptcy’. So where does speculative design start and the gambling and betting end? Behind each fabular frame is a four ratio problem. Each ratio reflects the level of sacrifice and self-restraint a society is willing to accept, against promises of prosperity and freedom. Some values seem to stabilise a frame while others cause collapse. Get the ratios right and we can have it all. Get them wrong and things get more desperate.
^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Duba...mayaclinic18
Whatsapp (+971581248768) Buy Abortion Pills In Dubai/ Qatar/Kuwait/Doha/Abu Dhabi/Alain/RAK City/Satwa/Al Ain/Abortion Pills For Sale In Qatar, Doha. Abu az Zuluf. Abu Thaylah. Ad Dawhah al Jadidah. Al Arish, Al Bida ash Sharqiyah, Al Ghanim, Al Ghuwariyah, Qatari, Abu Dhabi, Dubai.. WHATSAPP +971)581248768 Abortion Pills / Cytotec Tablets Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujeira, Ras Al Khaima, Umm Al Quwain., UAE, buy cytotec in Dubai– Where I can buy abortion pills in Dubai,+971582071918where I can buy abortion pills in Abudhabi +971)581248768 , where I can buy abortion pills in Sharjah,+97158207191 8where I can buy abortion pills in Ajman, +971)581248768 where I can buy abortion pills in Umm al Quwain +971)581248768 , where I can buy abortion pills in Fujairah +971)581248768 , where I can buy abortion pills in Ras al Khaimah +971)581248768 , where I can buy abortion pills in Alain+971)581248768 , where I can buy abortion pills in UAE +971)581248768 we are providing cytotec 200mg abortion pill in dubai, uae.Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman
In a tight labour market, job-seekers gain bargaining power and leverage it into greater job quality—at least, that’s the conventional wisdom.
Michael, LMIC Economist, presented findings that reveal a weakened relationship between labour market tightness and job quality indicators following the pandemic. Labour market tightness coincided with growth in real wages for only a portion of workers: those in low-wage jobs requiring little education. Several factors—including labour market composition, worker and employer behaviour, and labour market practices—have contributed to the absence of worker benefits. These will be investigated further in future work.
OJP data from firms like Vicinity Jobs have emerged as a complement to traditional sources of labour demand data, such as the Job Vacancy and Wages Survey (JVWS). Ibrahim Abuallail, PhD Candidate, University of Ottawa, presented research relating to bias in OJPs and a proposed approach to effectively adjust OJP data to complement existing official data (such as from the JVWS) and improve the measurement of labour demand.
Economic Risk Factor Update: June 2024 [SlideShare]Commonwealth
May’s reports showed signs of continued economic growth, said Sam Millette, director, fixed income, in his latest Economic Risk Factor Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
STREETONOMICS: Exploring the Uncharted Territories of Informal Markets throug...sameer shah
Delve into the world of STREETONOMICS, where a team of 7 enthusiasts embarks on a journey to understand unorganized markets. By engaging with a coffee street vendor and crafting questionnaires, this project uncovers valuable insights into consumer behavior and market dynamics in informal settings."
[4:55 p.m.] Bryan Oates
OJPs are becoming a critical resource for policy-makers and researchers who study the labour market. LMIC continues to work with Vicinity Jobs’ data on OJPs, which can be explored in our Canadian Job Trends Dashboard. Valuable insights have been gained through our analysis of OJP data, including LMIC research lead
Suzanne Spiteri’s recent report on improving the quality and accessibility of job postings to reduce employment barriers for neurodivergent people.
Decoding job postings: Improving accessibility for neurodivergent job seekers
Improving the quality and accessibility of job postings is one way to reduce employment barriers for neurodivergent people.
5 Tips for Creating Standard Financial ReportsEasyReports
Well-crafted financial reports serve as vital tools for decision-making and transparency within an organization. By following the undermentioned tips, you can create standardized financial reports that effectively communicate your company's financial health and performance to stakeholders.
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
Abhay Bhutada, the Managing Director of Poonawalla Fincorp Limited, is an accomplished leader with over 15 years of experience in commercial and retail lending. A Qualified Chartered Accountant, he has been pivotal in leveraging technology to enhance financial services. Starting his career at Bank of India, he later founded TAB Capital Limited and co-founded Poonawalla Finance Private Limited, emphasizing digital lending. Under his leadership, Poonawalla Fincorp achieved a 'AAA' credit rating, integrating acquisitions and emphasizing corporate governance. Actively involved in industry forums and CSR initiatives, Abhay has been recognized with awards like "Young Entrepreneur of India 2017" and "40 under 40 Most Influential Leader for 2020-21." Personally, he values mindfulness, enjoys gardening, yoga, and sees every day as an opportunity for growth and improvement.
3. Safe Harbor Clause
Some of the information in this presentation
may constitute forward-looking statements
which are subject to various uncertainties
and could cause actual results to differ
materially from those projected or implied.
These uncertainties are described in the
Company’s reports and exhibits filed with
the Securities and Exchange Commission.
4. Agenda For Today’s Presentation
Market and Strategy Overview
Business Unit Review
Summary
5. Largest Healthcare Services Company
Medical-
Medical-
Pharmaceutical Information
Pharmaceutical Information
Surgical
Surgical
Solutions Solutions
Solutions Solutions
Solutions
Solutions
$46 billion in $2.7 billion in $1 billion in
revenues revenues revenues
US and Hospitals Most comprehensive
Canadian HIT product line:
Physician
pharma software, services,
offices
distribution outsourcing
Nursing homes
Hospital and New clinical offering
retail Long-term care includes decision
automation facilities support, order entry
and digital medical
Pharmacy
imaging
outsourcing
Health
Solutions
6. McKesson Solutions Improve
Quality and Reduce Cost
Pharmaceutical and medical- Clinical, financial and
surgical distribution to all sites resource management
systems for hospital and
Automated drug
IDNs
dispensing for retail and
hospital pharmacies
Physician portal
Pharmacy outsourcing
Solution for
Medication Safety
Specialty pharmaceutical
distribution
HIT outsourcing
Services for payors, patients
and manufacturers
Unique Conversations with Customers At Higher Levels
7. Favorable Market Factors Drive
McKesson Growth
Aging population consumes more drugs, supplies
More sophisticated population demands higher quality
Employer and government focus on higher quality
Costs and incentives drive increased use of generics
Pharmacist and nurse shortage widens
Costs and quality concerns lead to increased disease
management
Expanding pipeline of higher-tech drugs
8. Strong Q2 FY03 Results
2nd Quarter
($ in millions, except EPS)
FY03 FY02
Revenues $10,282 $8,915 +15%
Operating Profit
Pharmaceutical Solutions $ 227 $ 179 +27%
Medical-Surgical Solutions 2 24 - 92%
Information Solutions 24 14 +79%
Net Income $ 124 $ 96 +29%
Diluted Earnings per Share $ 0.42 $ 0.32 +31%
Note: Before special items and discontinued operations,
not including sales to customers’ warehouses
9. Seven Quarters of Momentum
FY01 FY02 FY03
Q1
Q4 Q1 Q2 Q3 Q4 Q2
Revenue 17% 16% 19% 20% 16% 19% 15%
Y-O-Y
41% 41% 45% 58% 55%
EPS 35% 31%
Y-O-Y
18.0% 18.7% 19.4% 20.4% 22.0% 22.4% 22.9%
ROCC
All results exclude warehouse sales, special items and discontinued operations
discontinued
and include impact of FAS 142 in FY02
10. Agenda For Today’s Presentation
Market and Strategy Overview
Business Unit Review
Summary
11. Business Metrics Drive Results
Financial Success
To achieve the best financial
performance in the industry
Employee Satisfaction
Customer Satisfaction Metric-Driven
Execution To provide an environment
To have the most satisfied
that attracts and retains
customers in the industry
outstanding talent
Business Process Success
To fulfill our commitments to
our customers and to
each other
12. Supply Businesses Across All Sites
McKesson
McKesson
McKesson McKesson McKesson Health McKesson
McKesson McKesson McKesson Health McKesson
Medication
Medication
Pharmaceutical Automation Solutions Medical Surgical
Pharmaceutical Automation Solutions Medical Surgical
Management
Management
Distribution Retail Pharmacy Medical Pharmacy and Primary Care
Management Medication
Repackaging Hospital / Extended Care
Software and Management
Institutional
Informatics Acute Care
Services Services
International
Specialty
Pharmaceutical
Services
End-to-End Continuum of Services
Multiple Points of Leverage
Comprehensive North American Distribution
13. Pharmaceutical Solutions: Strong
Growth and Expanding Margins
U.S. pharmaceutical distribution revenues up
17%
Generic sales slow market growth but drive
margin expansion
Operating margin up 20 bp driven by
generics, strong pricing and increased sales
of related products and services
McKesson Canada revenues up 14% with
margin expansion
14. Pharmaceutical Solutions Margin
Momentum
9 Consecutive Quarters of Y-O-Y Operating Margin Expansion
3.50%
+55 bp in FY01 and FY02
3.25%
Operating Margin % of Revenues
+36 bp
3.00%
2.75% +70 bp
+22 bp +20 bp
2.50%
+20 bp
+34 bp +29 bp
2.25% +24 bp
+17 bp
-13 bp
2.00%
1.75%
1.50%
1.25%
1.00%
Q1 Q2 Q3 Q4
FY03
FY02
FY01
15. Pharmaceutical Solutions DC
Productivity
1.40
($Billions)
1.20
CAGR 37%
Annual Revenue/DC
1.00
0.80
0.60
0.40
0.20
0.00
FY98 FY99 FY00 FY01 FY02 FY03 EST
Note: Excludes Alaska and Hawaii
17. Balanced Profit Components in
Pharmaceutical Solutions
Inventory Profit Related products and services
McKesson Canada
Nadro
Branded product sourcing
Specialty Pharmaceuticals
Price increases
Automation
Special programs
Repackaging
Collaborative agreements
Disease Management
Pharmacy Outsourcing
Generic product sourcing
Payor Services
Zee Medical
18. Significant Generics Opportunity
Branded pharmaceuticals going off patent
$52B
Should drive significant generic growth
and margin expansion
• McKesson OneStop program
<$10B
• 20,000 pharmacy outlets
• Generic Rx GP$ and margin
higher than that of branded Rx
1998-2000 2001-2006
(proj.)
Source: IMS and analyst reports; internal McKesson analysis
19. Pharmaceutical Environment
Remains Positive
Market growth of 11-14% driven partially by
rapid penetration of generics, which creates
profit opportunities
Republican majority increases probability of
Medicare drug benefit through private sector
Drug price increases continue to be strong
Relationships with manufacturers are
cooperative and collaborative
20. Medical-Surgical Solutions Strategic
Value
Strategic role delivering supply chain
solutions
Strategic presence in alternate site market
Potential for shareholder value creation
22. McKesson Medical-Surgical:
What We’re Doing
Install experienced leadership with track record for
successful turnaround and augment with resources
Improve financial and operating processes
Execute DC network consolidation
Complete ERP system implementation
Increase private brand sales
Stabilize this year with margin improvement
expected in FY04
23. Information Solutions Market
Leadership
Employee
Financial Solution Employee
Financial Solution
Market Share
Market Share Expertise
Strength Portfolio Expertise
Strength Portfolio
$1 billion 60% of health Most comprehensive 6,300
revenues systems employees
Best-of-class
15% of 82% of covered 1,250 R&D
•Software
revenue goes lives • PACS
850 customer
to R&D •Services
Largest / most support
investment •Outsourcing
profitable
500 clinicians
•Consulting
International HIT
•Content
business
•Connectivity
24. Customer Needs Drive Demand for IT
Solutions
Processes
IT Demand Clinical Needs
Drivers Reduce variability
Care Delivery
Improve MD connectivity
Reduce medical errors
Revenue Cycle Needs
Improve cash flow
Core
Billing & Reduce rework
Process
Claims
Analyze financial performance
Improvements
Resource Management Needs
Standardization of supplies
Purchasing &
Improve order management
Supply
Improve product movement
25. Information Solutions: Expanding
Margin and Clinical Momentum
Revenues up 16%, software up 20%
Operating margin up 309 bp to 8.78%
Software bookings up 43%
Horizon Expert Orders GA on schedule by
12/31/02
20 Horizon Expert Orders sales to date
10 in implementation by fiscal year end
26. Information Solutions Operating
Margin Momentum
+309 bp
9.00%
6 consecutive quarters of Y-O-Y
8.50%
Operating Margin expansion
8.00%
+296 bp
7.50%
7.00%
+855 bp
6.50% +534 bp
6.00% +502 bp
5.50%
5.00%
+290 bp
4.50%
4.00%
Q1 Q2 Q3 Q4 Q1 Q2
FY02 FY03
27. Information Solutions Positive Outlook
Growing Demand for Clinical Products
McKesson Positioned for Clinical Leadership
Margin Expansion Strategies
Improving revenue mix
Leveraging existing infrastructure
28. Agenda For Today’s Presentation
Market and Strategy Overview
Business Unit Review
Summary
29. FY00 to FY03 Achievements
Highest revenue growth and largest operating
margin expansion in pharmaceutical distribution
industry over the past 2-1/2 years
Largest increase in customer satisfaction, more
new product introductions and largest operating
margin expansion in healthcare information
technology industry over past 3 years
EPS growth above 30% for seven consecutive
quarters despite erosion in medical-surgical
segment operating margin
30. McKesson Differentiated Solutions
Presbyterian Healthcare
Spartanburg Health Systems
Solaris Health Systems
OTN
Wal-Mart
Together Rx Card
31. Goals for Delivering Sustained
Financial Performance
Industry-leading solutions and margin
expansion in Pharmaceutical Solutions
Clinical leadership, continued new product
innovation and continued margin expansion
in Information Solutions
Financial turnaround and return to historical
operating margins in Medical-Surgical
Solutions
Value Creation for Customers and Shareholders